Key facts
- Ncardia’s last known valuation is $174.0M.
- It has raised $129.7M; the latest was Later Stage VC ($51.9M) in Sep 2024.
- Notable investors include Noshaq, InnovationQuarter, SambrInvest, Federal Holding and Investment Company (Brussels), Société Régionale d'Investissement de Wallonie — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ncardia
- ·The full record, as it builds
Funding rounds
No funding rounds for Ncardia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ncardia
Operator of a biotechnology company intended to provide technologies to expedite drug discovery and development processes. The company uses human induced pluripotent stem cells (hiPSCs) technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers and drug discovery companies to bring predictive human disease biology and accelerate drug discovery.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2010
- Employees
- 55
- Website
- ncardia.com/
- Ownership
- Privately Held (backing)
Ncardia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ncardia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ncardia in its N-PORT filings yet. We sweep new filings monthly.